FindTrial
Sign In

What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants?

What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants? - WOEST 3 trial

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49131
Enrollment
2500
Registered
2020-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart attack myocardial infarction

Interventions

Random (1:1) allocation to dual therapy (OAC + 1 year P2Y12 inhibitor) versus triple therapy (OAC + 1 year P2Y12 inhibitor + 1-12 moths ASA).

Sponsors

Sint Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Over 18 years of age Acute coronary syndrome with elevated cardiac enzymes Atrial fibrillation with long-term indication for oral anticoagulation

Exclusion criteria

Exclusion criteria: Severe bleeding in past 3 months Known coagulopathy Contra-indications for intended medication (NOAC, P2Y12-remmer, ASA) eGFR < 15 min/kg/1.73m2

Design outcomes

Primary

MeasureTime frame
Primary efficacy endpoint: composed endpoint of all-cause death, MI, stroke, systemic embolism, stent thrombosis. Primary safety endpoint: ISTH major + clinically relevant non-major bleeding.—

Secondary

MeasureTime frame
Secondary endpoints: separate components of primary endpoints, net clinical benefit, quality of life.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)